• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate

    Drug Development For Startups

    Metrion, LifeArc Extend Neuroscience Alliance
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Emergent BioSolutions

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Baxter BioPharma Solutions

    PCI Pharma Services

    Adare Pharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Biogen Expands Neurological Disease R&D

    Enters deals with C4 Therapeutics and Skyhawk worth nearly $500 million when combined

    Biogen Expands Neurological Disease R&D
    Biogen Expands Neurological Disease R&D
    Related CONTENT
    • AbbVie, Tizona in Strategic Immunotherapy Alliance
    • Bristol-Myers Squibb, Celgene Ink $74B Merger
    • Alkermes, Biogen Submit NDA to FDA
    • Celgene Licenses Two Dragonfly Immunotherapy Candidates
    • Biogen Licenses ALS Treatment from Ionis
    01.04.19
    Biogen and C4 Therapeutics have entered into a strategic collaboration to investigate the use of C4’s novel protein degradation platform to discover and develop potential new treatments for neurological conditions, such as Alzheimer’s disease and Parkinson’s disease.
     
    C4 will provide expertise and research services in targeted protein degradation and Biogen will provide neuroscience expertise and drug development capabilities. Biogen and C4 will research potential targets together and Biogen will advance candidates for development and potential commercialization. Biogen will pay C4 up to a total of $415 million in upfront and potential future milestone payments plus potential future royalties. Biogen expects to record a research and development expense of $15 million to $25 million in the fourth quarter of 2018 related to this transaction.
     
    “C4T’s platform enables the discovery of novel molecules that take advantage of endogenous protein degradation mechanisms to target disease-causing proteins,” said Michael Ehlers, executive vice president, research and development, Biogen. “This new collaboration with C4 complements our broader research strategy to develop potential therapies for neurological conditions across multiple modalities. We look forward to discovering new potential therapeutic options for diseases that currently have limited-to-no treatment options available.”
     
    Andy Phillips, president and chief executive officer, C4 Therapeutics, said, “We are excited to work with our Biogen colleagues to take on the challenge of researching new potential therapies for Alzheimer’s disease, Parkinson’s disease and other devastating neurological diseases. Our approach of using the cell’s innate mechanisms to eliminate specific, disease-causing proteins is a promising new way to tackle the challenges of central nervous system diseases. Together with Biogen, a global leader in neuroscience, we are eager to embark on this important effort.”
     
    In another deal, with Skyhawk Therapeutics Biogen has formed a collaboration in which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization.
     
    The agreement grants Biogen an exclusive license to worldwide intellectual property rights on research-stage therapeutic candidates for the treatment of multiple sclerosis (MS), spinal muscular atrophy (SMA) and additional neurological disorders. As part of the agreement, Skyhawk received an upfront payment of $74 million from Biogen and may receive potential future milestone payments and royalties. A portion of the upfront payment will be allocated to future research services, with the remainder expensed in the first quarter of 2019 as research and development.
     
    "Skyhawk's platform offers a powerful approach to target neurological conditions using selective RNA-modulating small molecules, creating exciting possibilities for potential new therapies," said Biogen’s Mr. Ehlers. “This collaboration exemplifies Biogen's commitment to joining forces with innovative companies with the goal of improving the lives of patients living with complex neurological diseases."
     
    Bill Haney, co-founder and chief executive officer, Skyhawk, said, "Biogen is a leading neuro-focused biopharmaceutical company with a compelling history of drug development across a range of challenging neurological conditions. Their strong scientific culture has already produced a series of leading global therapeutics. We look forward to working with their team with the goal of potentially enhancing the treatment options we could bring to the neuroscience community."
    Related Searches
    • patients
    • intellectual property
    • discovery
    • contractpharma
    Suggested For You
    AbbVie, Tizona in Strategic Immunotherapy Alliance  AbbVie, Tizona in Strategic Immunotherapy Alliance
    Bristol-Myers Squibb, Celgene Ink $74B Merger Bristol-Myers Squibb, Celgene Ink $74B Merger
    Alkermes, Biogen Submit NDA to FDA Alkermes, Biogen Submit NDA to FDA
    Celgene Licenses Two Dragonfly Immunotherapy Candidates Celgene Licenses Two Dragonfly Immunotherapy Candidates
    Biogen Licenses ALS Treatment from Ionis Biogen Licenses ALS Treatment from Ionis
    Celgene, Dragonfly Expand Immunotherapy Alliance Celgene, Dragonfly Expand Immunotherapy Alliance
    Samsung BioLogics, Biogen Conclude Asset Transfer  Samsung BioLogics, Biogen Conclude Asset Transfer
    Dragonfly, Merck Enter Strategic Collaboration Dragonfly, Merck Enter Strategic Collaboration
    Codiak BioSciences Appoints EVP Codiak BioSciences Appoints EVP
    Atara, Moffitt Cancer Center Enter Collaboration Atara, Moffitt Cancer Center Enter Collaboration
    Structured Immunity, Medigene AG Enter Collaboration Structured Immunity, Medigene AG Enter Collaboration
    Amgen Reveals Executive Transition Plans Amgen Reveals Executive Transition Plans
    PPD Names New CHRO PPD Names New CHRO
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    05	Merck 05 Merck

    Related Breaking News

    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Janssen, TenNor Enter NTM Research Pact

      Janssen, TenNor Enter NTM Research Pact

      To leverage TenNor’s multitargeting drug conjugation platform to discover new therapies to treat nontuberculous mycobacteria diseases.
      Contract Pharma Staff 01.18.21

    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News
      EVOQ Therapeutics and Amgen Partner

      EVOQ Therapeutics and Amgen Partner

      Collaborate on the discovery and development of novel drugs for autoimmune disorders.
      Contract Pharma Staff 01.13.21

    • Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | R&D
      Almac Sciences Secures Support from Invest NI

      Almac Sciences Secures Support from Invest NI

      Accelerates enzyme discovery program.
      Contract Pharma Staff 01.13.21


    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
      Adagene Achieves CAR-T Collaboration Milestone

      Adagene Achieves CAR-T Collaboration Milestone

      Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.
      Contract Pharma Staff 01.12.21

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      Cyclolab and EpiPharma Form Joint Venture

      Cyclolab and EpiPharma Form Joint Venture

      Will develop and commercialize Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.
      Contract Pharma Staff 01.11.21

    • Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | R&D
      Mogrify Enters Research Collaboration with MRC LMB

      Mogrify Enters Research Collaboration with MRC LMB

      Research project aims to develop novel protein expression systems via cell reprogramming.
      Contract Pharma Staff 01.11.21


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Laboratory Testing
      Biohaven Acquires Remaining Stake in Kleo Pharmaceuticals

      Biohaven Acquires Remaining Stake in Kleo Pharmaceuticals

      Enters exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from Spiegel Lab.
      Contract Pharma Staff 01.08.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      BrickBio Inks ADC Co-Development Deal

      BrickBio Inks ADC Co-Development Deal

      To co-develop a therapeutic antibody drug conjugate (ADC) with a large pharmaceutical company.
      Contract Pharma Staff 01.06.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology
      Lantern Pharma Launches ADC Program

      Lantern Pharma Launches ADC Program

      Will leverage RADR artificial intelligence platform to target solid tumors and blood cancers through agreement with Califia Pharma.
      Contract Pharma Staff 01.04.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Chemistry | Drug Development | Industry News
      Oncorus to Build GMP Viral Immunotherapy Mfg. Facility

      Oncorus to Build GMP Viral Immunotherapy Mfg. Facility

      88,000 sq.-ft. facility in Andover, MA will support multi-product pipeline of intratumorally and intravenously administered viral immunotherapies.
      Contract Pharma Staff 01.04.21

    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Evotec, BMS Advance Targeted Protein Degradation Projects

      Evotec, BMS Advance Targeted Protein Degradation Projects

      The first two targets transition into drug discovery after completing a comprehensive target validation process.
      Contract Pharma Staff 12.17.20

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      INOVIO to Develop dMAb COVID Treatments under DARPA Grant

      INOVIO to Develop dMAb COVID Treatments under DARPA Grant

      $37.6 million grant will leverage AstraZeneca's monoclonal antibody and INOVIO's dMAb technologies in the fight against COVID-19.
      Contract Pharma Staff 12.15.20


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Lilly to Acquire Prevail Therapeutics in $1B Deal

      Lilly to Acquire Prevail Therapeutics in $1B Deal

      Adds a new drug discovery and development modality and creates a gene therapy program anchored by Prevail's portfolio of neuroscience assets.
      Contract Pharma Staff 12.15.20

    • Breaking News | Clinical Trials | CRO News | Drug Development
      Ergomed Acquires MedSource

      Ergomed Acquires MedSource

      Specialist oncology and rare disease CRO further expands Ergomed’s presence in the U.S. market.
      Contract Pharma Staff 12.15.20

    • Breaking News | cGMP Manufacture | Drug Development | Industry News | R&D
      Ascentage Selects PharmaBlock as Preferred Provider

      Ascentage Selects PharmaBlock as Preferred Provider

      PharmaBlock will support Ascentage in accelerating its drug development pipeline with R&D, manufacturing capacity, and technological solutions.
      Contract Pharma Staff 12.11.20

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Virtual Clinical Trials: The Future Of Dermatology Studies
    Breaking News
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    • JS Bio and Etta Biotech Advancing Partnership
    • Intravacc Completes Project for Provention Bio’s Vax Candidate
    • Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    BGG Obtains U.S. Patent on AstaZine Natural Astaxanthin for Heart Function During Exercise
    Qualitas Health/iwi Raises $10 Million in Investment Round
    Aker BioMarine Expands Krill Portfolio with Novel Protein Hydrolysate
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CHF Solutions Appoints CEO
    Freehand Partners with Imperial Medial Solutions
    Intersect ENT Announces CMS Approval of Coding Application for Sinus Implant
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    NovaQuest Private Equity Acquires CoreRx
    JS Bio and Etta Biotech Advancing Partnership
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Marino Belotti Presents New Website
    Essence Cosmetics Expands in the U.S.
    Sigma Beauty Launches 'Brush Care' Sets at Sephora
    Happi

    Latest Breaking News From Happi

    Mix:Bar Launches at Target
    Crystal Deodorant Unveils Magnesium-Enriched Sticks
    Euromonitor Reveals Top 10 Global Consumer Trends for 2021
    Ink World

    Latest Breaking News From Ink World

    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Packaging Printing Market Worth $433.4 Billion by 2025: MarketsandMarkets
    O-I Foundation Gifts $50k to Facilitate COVID-19 Vaccine Access
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Honeywell Delivered 225 Million Masks in December
    Techtextil, Texprocess Postponed to 2022
    Super Strong Inks Survive Tough Environments
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints SVP of Operations
    DePuy Synthes Receives 510(k) FDA Clearance for VELYS Robotic-Assisted Solution
    OrthoPediatrics Expands Agent Network in Three European Countries
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login